Noble Life Science Partners
Nathan Cali

Press Releases

Aequus Retains Investor Relations Representative

VANCOUVER, BC–May 26, 2015 - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (“Aequus” or the “Company”) is pleased to announce, subject to TSX Venture Exchange (“TSX-V”) acceptance, that the Company has retained Brisco Capital Partners Corp. (“Brisco”) as its Investor Relations representative. Brisco, founded by Scott Koyich, is a Calgary based consultancy with a North American presence. Brisco will assist Aequus in maintaining contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and its activities. Brisco takes a full service approach and provides creative and effective investor relations programs for Canadian public companies.

Under the terms of the agreement, Aequus will compensate Brisco at a rate of $7,500 CAD per month + applicable taxes, for a period of one year. Aequus has also agreed to grant Brisco 150,000 stock options. As per TSX-V policies, the options will vest quarterly over a period of one year, and shall be subject to TSX-V approval and the provisions of the Company's Stock Option Plan.

About Aequus Pharmaceuticals Inc.:

Aequus Pharmaceuticals Inc. is a Vancouver-based specialty pharmaceutical company focused on enhancing delivery methods for approved drugs that are limited by non-compliance, high frequency dosing, first-pass metabolism side-effects, painful injections, or where the therapeutic profile can be improved by making a long-acting alternative available. Aequus’ early-stage pipeline is focused on neurology and psychiatry products where there is a high medical need for an alternate route of delivery. Aequus’ lead-program, AQS-1301, is a once-weekly transdermal formulation of aripiprazole in development for the potential treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia, and major depressive disorder. AQS-1301 is currently in pre-clinical development and will be entering Proof of Concept clinical studies in the second half of 2015. For further information, please visit www.aequuspharma.ca.

Aequus Forward-Looking Statement

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans and our investor relations strategy.

Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions.

In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Long-Form Prospectus dated February 18, 2015, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

CONTACT INFORMATION


Email: investors@aequuspharma.ca
Phone: 604-336-7906

Back to All News